Distinct lung microbiota associate with HIV-associated chronic lung disease in children. by Bhadriraju, Sudha et al.
1
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16186  | https://doi.org/10.1038/s41598-020-73085-1
www.nature.com/scientificreports
Distinct lung microbiota associate 
with HiV‑associated chronic lung 
disease in children
Sudha Bhadriraju1,5, Douglas W. Fadrosh2,5, Meera K. Shenoy2, Din L. Lin2, Kole V. Lynch2, 
Kathryn McCauley2, Rashida A. Ferrand3,4, Edith D. Majonga3, Grace McHugh3, 
Laurence Huang1, Susan V. Lynch2,5 & John Z. Metcalfe1,5*
Chronic lung disease (CLD) is a common co-morbidity for HIV-positive children and adolescents on 
antiretroviral therapy (ART) in sub-Saharan Africa. In this population, distinct airway microbiota 
may differentially confer risk of CLD. In a cross-sectional study of 202 HIV-infected children aged 
6–16 years in Harare, Zimbabwe, we determined the association of sputum microbiota composition 
(using 16S ribosomal RNA V4 gene region sequencing) with CLD defined using clinical, spirometric, 
or radiographic criteria. Forty-two percent of children were determined to have CLD according to our 
definition. Dirichlet multinomial mixtures identified four compositionally distinct sputum microbiota 
structures. Patients whose sputum microbiota was dominated by Haemophilus, Moraxella or Neisseria 
(HMN) were at 1.5 times higher risk of CLD than those with Streptococcus or Prevotella (SP)-dominated 
microbiota (RR = 1.48, p = 0.035). Cell-free products of HMN sputum microbiota induced features of 
epithelial disruption and inflammatory gene expression in vitro, indicating enhanced pathogenic 
potential of these CLD-associated microbiota. Thus, HIV-positive children harbor distinct sputum 
microbiota, with those dominated by Haemophilus, Moraxella or Neisseria associated with enhanced 
pathogenesis in vitro and clinical CLD.
In 2019, 1.8 million children aged less than 15 years were living with HIV, 90% in sub-Saharan  Africa1. Global 
scale-up of ART has resulted in a dramatic improvement in survival, with children accessing ART surviving 
to  adulthood2,3. Although acute bacterial pneumonias, disseminated M. avium complex, Pneumocystis jeroveci 
pneumonia, and lymphocytic interstitial pneumonitis have declined in this age group since the pre-ART  era4, 
respiratory disease remains a major cause of morbidity and mortality in HIV-infected  children2.
Chronic respiratory symptoms, including cough (21–60%), dyspnea (12–18%), and exertional hypoxemia 
(12–38%), are common among older HIV-positive older  children3. Further, HIV-positive adolescents have 
reduced exercise tolerance and spirometric abnormalities including lower forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) relative to HIV-negative  controls2,3. Although the pathogenesis 
of HIV-associated chronic lung disease (CLD) remains unknown, high resolution chest computed tomography 
(HRCT) findings of decreased attenuation and bronchiectasis suggest small airways pathology, possibly due to 
recurrent pulmonary infections and HIV-mediated airway  inflammation3.
Several risk factors have been implicated in the pathogenesis of HIV-CLD including HIV-mediated systemic 
immune activation and chronic  inflammation3,5. Recent study of the lung microbiota and its mechanistic role 
in mediating the lung’s inflammatory response has revitalized our understanding of the pathogenesis of chronic 
lung diseases like  asthma6–8. Bacterial products, ligands, and metabolites, and the host response to them can 
promote inflammation and increase lung susceptibility to oxidative stress, resulting in increased risk for acute 
respiratory infection and chronic lung  disease7.
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Our group previously demonstrated that three distinct airway microbiota exist in HIV-infected adults with 
pneumonia, and that these microbiota are associated with distinct airway mucosal inflammatory profiles and 
short-term  mortality9. Here, we extend our work to children and adolescents with HIV on ART to examine the 
association of airway microbiota with clinical evidence of CLD. We hypothesized the presence of distinct sputum 
microbiota among children with CLD versus those without, and that in human airway epithelial cell experiments 
such microbiota would induce inflammation mechanistically important to CLD pathobiology.
Results
Study participants. We recruited a total of 202 HIV-positive children aged 6–16 years stable on ART. The 
overall prevalence of clinical indicators of HIV-CLD was 42.1% (n = 85). A total of seven children had abnormal 
spirometry, 32 had chronic cough and dyspnea, and the remainder had abnormal CT imaging. Participants with 
CLD were older than those without CLD (11.6 vs. 10.6 years; p < 0.01); other demographic features were similar 
(Table  1). Time on ART, CD4+ T-cell count, and proportion virologically suppressed did not differ between 
groups. More than one-third of participants (38%) had experienced one or more prior episodes of tuberculosis 
treatment, and this was similar among those with (41.2%) or without (35.9%) CLD. A total of 151 sputum sam-
ples were collected and processed for 16S rRNA biomarker sequencing. Participants whose sputum samples were 
unable to be sequenced were statistically younger (9.8 vs. 10.8 years; p = 0.01) and were younger at time of HIV 
diagnosis (4.4 vs. 5.3 years; p = 0.01) relative to those whose samples were processed for 16S rRNA biomarker 
sequencing; other demographic and clinical characteristics were similar (Supplemental Table 2).
Determination of sputum microbiota structures. Sputum samples undergoing 16S rRNA biomarker 
sequencing attained a median of 184,171 high quality reads per sample (range = 78,309–396,824 reads), which 
after filtering and rarefying to 73,265 were binned into a total of 365 operational taxonomic units (OTUs). Math-
ematical modeling of OTU frequencies using Dirichlet multinomial mixtures (DMM) can be applied to 16S 
rRNA datasets to determine whether distinct microbiota structures exist and repeat across participants within 
a cohort. Using a Laplace approximation (Fig. 1a), DMM indicated that 4 significantly distinct bacterial sputum 
microbiota structures (DMM1-4) existed in the dataset. Principal components analyses confirmed that these 
four microbiota states (DMM1-4) explained a reasonable proportion of observed variance in sputum microbiota 
composition observed in our dataset  (R2 = 0.207, p < 0.001; Fig. 1b). We next examined the distribution of taxa 
within each of these sputum DMM clusters and noted that each was dominated by a distinct bacterial genus 
(Fig. 1c,d). DMM1 sputum microbiota were primarily dominated by Streptococcus, DMM2 by Prevotella, DMM3 
by Haemophilus and DMM4 by Moraxella. Indeed, using dominant taxon identity as a classifier for each sample 
increased our capacity to explain the observed variance in sputum microbiota composition (PERMANOVA, 
 R2 = 0.492, p < 0.001), and indicated that dominant taxon classification was broadly consistent with the DMM 
clusters identified.
Association of sputum microbiota with HIV-associated chronic lung disease. Using dominant 
taxon as a classifier, we noted that subjects with a Haemophilus-, Moraxella- or Neisseria-dominated sputum 
microbiota (HMN group; n = 35) were more likely to be associated with CLD relative to those with either a Strep-
tococcus or Prevotella-dominated airway microbiota (SP group, n = 116; RR = 1.50, p = 0.024; Table 2). Time on 
ART (5.0 vs. 4.7 years, p = 0.45), CD4+ T-cell count (717 vs. 727 cells/µL, p = 0.66), and proportion virologically 
suppressed (66% (n = 23/35) vs. 71% (n = 79/111); p = 0.69) did not differ statistically between the HMN and 
Table 1.  Characteristics of study participants. SD standard deviation, CLD chronic lung disease, TB 
tuberculosis, HRCT high resolution chest computed tomography. *p < 0.05 = significant; †Wilcoxon-rank sum 
test; ‡Chi-square test or Fisher’s exact test; §”Height for age" value ≤ two standard deviations of the WHO Child 
Growth  Standards45.
Participants without CLD (n = 117) Participants with CLD (n = 85) p-value
Age (years), mean (SD) 10.6 (2.4) 11.6 (2.8) 0.006*
Female sex, n (%) 54 (46.2%) 37 (43.5%) 0.71
Age at diagnosis (years), mean (SD) 4.6 (2.8) 5.8 (3.2) 0.008*
Duration of ART at recruitment (years), mean (SD) 4.8 (2.5) 4.8 (2.8) 0.93
CD4 + at enrollment (cells/μL), mean (SD) 739 (278.9) 737 (421.4) 0.97
Viral load at enrollment (copies/mL), median (IQR)† 19 (49) 20 (328) 0.12
Proportion virally suppressed (< 75 copies/mL) 72% 68% 0.54
Previous TB  treatment‡ 42 (35.9%) 35 (41.2%) 0.45
Treated with ≥ 1 course of antibiotics in the past 
12 months‡ 27 (23.1%) 18 (21.2%) 0.75
Stunted  growth‡§ 40 (34%) 32 (37.6%) 0.64
Radiographic features on HRCT ‡
Bronchial wall thickening 0 (0%) 69 (95.8%) 0.001*
Bronchiectasis 0 (0%) 28 (38.9%) 0.04*
Bronchiectasis and mosaic attenuation 0 (0%) 23 (31.9%) 0.07
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SP groups. The strongest association with chronic lung disease occurred among HIV-infected children with a 
Neisseria-dominated sputum microbiota, though these individuals were rare in our cohort.
HMN sputum microbiota induce epithelial cell inflammation. We hypothesized that increased risk 


































































Figure 1.  (A) LaPlace approximation of Dirichlet Multinomial Mixture Model fit indicating that four distinct 
sputum microbiota structures are evident in our pediatric cohort. (B) Distinct microbiota structures identified 
by Dirichlet multinomial mixture model (DMM) explain approximately 20% of variance in sputum microbiota 
composition (Weighted UniFrac). (C) Stacked bar graphs indicate that each DMM cluster is dominated by a 
distinct bacterial genus. (D) Distinct sputum microbiota dominated by Prevotella, Streptococcus, Haemophilus, 
Moraxella and Neisseria exist in the airways of children with HIV infection.
Table 2.  Distinctly dominated sputum microbiota associate with risk of HIV-associated chronic lung disease. 
Values in bold were considered statistically significant at p ≤ 0.05.
RR p value
Haemophilus/Moraxella/Neisseria vs. Streptococcus/Prevotella 1.500 0.024
Haemophilus vs. Moraxella 1.154 0.746
Haemophilus vs. Neisseria 0.577 0.001
Haemophilus vs. Streptococcus 1.435 0.081
Haemophilus vs. Prevotella 1.500 0.297
Moraxella vs. Neisseria 0.500 0.090
Moraxella vs. Streptococcus 1.244 0.608
Moraxella vs. Prevotella 1.300 0.626
Neisseria vs. Streptococcus 2.488  < 0.001
Neisseria vs. Prevotella 2.600 0.007
Streptococcus vs Prevotella 1.045 0.905
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airway microbiota. Because we had observed that the HMN group was at significantly higher risk of CLD com-
pared with the SP group, we analyzed a representative sample of 50 (of 151) sputum samples from children with 
HIV-CLD belonging to the HMN (n = 19) or SP [S (n = 18), P (n = 13)] groups for their capacity to promote 
epithelial inflammation. Human airway epithelial A549 cells were treated with cell-free sputum extracts for 24 h. 
Data from A549 exposure to sterile sputum fluid (SSF) was considered in our analyses if > 60% cell viability was 
observed following 24 h of SSF treatment. The majority of SSF exposures (n = 45/50) resulted in > 60% viability 
(Supplemental Figure 3). Q-PCR based expression analysis of 9 genes involved in epithelial inflammatory pro-
cesses (IL8, IL33, IL1β, CXCL10, TGFβ), barrier function (Occludin, E-cadherin, Muc5AC), and response to 
microbes (TLR9) were assessed (Supplemental Figure 4). Principal coordinate analysis indicated that the expres-
sion profile of these 9 genes was significantly distinct based on whether sputum samples belonged to the HMN or 
SP groups (PERMANOVA,  R2 = 0.16, p = 0.001; Fig. 2). This indicates that the products of these distinct sputum 
microbiota differentially interact with airway epithelia to induce distinct responses.
More specifically, we noted that sputum products of HMN microbiota (compared with those of the SP group) 
induced significantly increased expression of IL-1β (p = 0.01), IL-33 (p = 0.01) and E-cadherin (0.004), which 
play a role in cell to cell adherence, as well as decreased expression of Muc5AC (p < 0.0001) associated with 
mucin secretion, TGFβ (p = 0.0007) which is considered anti-inflammatory, and TRL9 (p = 0.01) which senses 
and responds to microbial DNA (Fig. 3).
Discussion
HIV-associated chronic lung disease affects up to one-third of children and adolescents on long-term ART in 
sub-Saharan  Africa3, but little is understood about its pathophysiology. To our knowledge, our study is the first 
to apply culture-independent 16S rRNA gene sequencing to sputum to investigate molecular mechanisms under-
lying HIV-CLD pathogenesis. We identified four compositionally distinct microbiota profiles in the sputum of 
older children with HIV consisting of microbiota dominated by Streptococcus, Haemophilus, Prevotella, Morax-
ella, or Neisseria. Children with Haemophilus-, Moraxella-, or Neisseria-dominated sputum microbiota (HMN 
group) were 1.5 times more likely to have CLD compared to children dominated by Streptococcus or Prevotella 
(SP group). In addition, cell-free products of HMN sputum induced a distinct epithelial gene expression signature 
characterized by increased expression of pro-inflammatory cytokines and decreased expression of Muc5AC. 
Muc5AC stimulates anti-inflammatory TGFβ and produces mucin-5AC10, a gel-forming glycoprotein responsible 
for mucosal protection from infection and chemical damage, suggesting that airway colonization by microbiota 
in the HNM group induce a higher degree of inflammation. Therefore, if confirmed, our findings suggest that 
interventions targeting modulation of lung microbiota could have important treatment implications for CLD.
Microbiota dominated by Neisseria, Moraxella, or Haemophilus are associated with chronic respiratory 
diseases including asthma, COPD, and chronic rhinosinusitis among HIV-uninfected adult and pediatric 
 populations6,11–15. In contrast, these findings have not consistently been supported in HIV-positive populations, 
Figure 2.  PCoA plot of epithelial gene expression profiles induced following exposure of cultured epithelial 
cells to sterile products of the HMN or SP patient sputum. Data indicates that sputum from the Haemophilus-
Moraxella-Neisseria (HMN) group induces a significantly distinct epithelial gene expression response from that 
induced by the sterile sputum products of the Prevotella-Streptococcus (PS) group.
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where Streptococcus and Prevotella dominance has been associated with pulmonary inflammation, COPD, 
and short- and intermediate-term mortality among HIV-positive Ugandan adults hospitalized with acute 
 pneumonia9,16,17. The association of Streptococcus and Prevotella microbiota with a lower relative risk of pedi-
atric HIV-CLD in our study could be explained by three factors. First, a distinct bacterial composition among 
children due to less lifetime ART exposure, less immune system maturation and expected microbiota establish-
ment due to peri-natal acquisition of HIV, more frequent antibiotic use, and differing response to vaccinations 
and environmental  exposures15. Second, 16S rRNA sequencing currently classifies dominant microbes to the 
genus level, and we cannot rule out genomic differences in species or strains within these genera as accounting 
for differences in disease associations. Third, a microbiota’s functional role in host immune modulation is driven 
by microbe-microbe and microbe-host interactions and resulting antigenic and metabolic products, rather than 
the relative abundance of any individual  taxa9,18,19. Therefore, Haemophilus, Moraxella, Neisseria, Streptococcus 
and Prevotella all represent a spectrum of pathogenic potential in HIV-positive children, with HMN as a group 
exerting enhanced inflammatory effects and conferring an increased relative risk of HIV-CLD.
Microbe-mediated modulation of epithelial gene expression provides a critical mechanistic link between 
HMN community composition and HIV-CLD pathogenesis. We demonstrate that the HMN group is associated 
with significantly higher levels of pro-inflammatory cytokines compared to Streptococcus- or Prevotella-domi-
nated sputum samples. These include IL-1β, an important epithelial cell-to-cell signal that stimulates macrophage 
accumulation in early  infection20, IL-33, a known driver of type-2 immune response during  infection21, and 
E-cadherin, a protein important for epithelial barrier integrity, which has been shown to be down-regulated 
with increased IL-3321.
Our findings suggest that Moraxella and Haemophilus may be principal drivers of airway inflammation in 
HIV-CLD. Molecular mechanisms of immune modulation by Moraxella catarrhalis (M. catarrhalis) and non-
capsulated Haemophilus influenza (NHi) are well-established in  COPD22–24. Certain groups of Moraxella (e.g., 
Moraxella catarrhalis) are known lung  pathogens25 able to invade host epithelial cells and survive as intracellular 

































































































































































Figure 3.  Comparative analysis of epithelial gene expression induced following exposure of cultured epithelial 
cells to sterile products of Haemophilus-Moraxella-Neisseria (HMN) or Prevotella-Streptococcus (PS) sputum.
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infiltration in lung epithelial cells through an increase in IL-8  production22,26. NHi has also been known to 
invade host epithelial cells, escape host immune response, form biofilms, and increase severity and duration of 
co-occurring viral  infections18,23,24. It has been implicated in initiating a robust TLR-mediated cellular immune 
response via NF-kB activation, increasing IL-1β and IL-8 production and subsequent neutrophil infiltration into 
the  lung24,26,27. In addition, Moraxella, Haemophilus and Neisseria all contain homologous lactoferrin-binding 
and transferrin-binding proteins that allow them to sequester local iron sources to outgrow other commensals 
and form polymicrobial biofilms that are associated with COPD  exacerbations28–30. Though extrapolations from 
pro-inflammatory mechanisms of M. catarrhalis and NHi in COPD remain theoretical, they provide biological 
plausibility to our hypothesis.
Our data further illustrate decreased expression of TGF-β and TLR9 in the HMN group. In HIV-infected 
patients, TGF-β functions in various ways as an anti-inflammatory agent in both innate immunity, such as 
suppressing survival and proliferation of B lymphocytes, and adaptive immunity, such as inhibiting mTOR-
mediated NF-κB  activation31. Moraxella and Haemophlius-mediated NF-κβ activation and resultant epithelial 
inflammation, as detailed above, likely overwhelms TGF-β function in HMN subjects. TRL9 similarly participates 
in recognizing bacterial and viral DNA at the lung epithelial surface, in attenuating pro-inflammatory innate 
and adaptive immune responses, and in tissue  homeostasis32. A blunting of these functions likely contributes to 
increased pro-inflammatory cytokines in HMN subjects.
Our study has several potential limitations. First, our study was cross-sectional and unable to determine the 
temporal relationship of the oral microbiome to development or progression of clinical chronic lung disease in 
HIV-infected older children. Further, the effect sizes of examined variables to the microbiome were relatively 
small, indicating that other factors might have contributed to the microbiome alterations and development of 
chronic lung disease. Second, our in vitro epithelial gene expression analysis provided a plausible explanation of 
lung microbe function in mucosal immune modulation, but we did not carry this forward to in vivo verification. 
Third, HRCT was only performed for participants with findings noted on plain chest radiograph; since computed 
tomography is much more sensitive for lung pathology, our prevalence estimate for radiographic abnormality 
likely represents a lower bound. Fourth, we did not include a control group of children without HIV infection. 
Relative to adults without HIV infection, adults with advanced HIV infection demonstrate decreased oral micro-
bial α  diversity17,33, and adults with well-controlled HIV infection demonstrate increases in relative abundance 
of Veillonella, Streptococcus, and Lactobacillus34. The degree to which these findings extend to HIV-uninfected 
children and adolescents living in sub-Saharan Africa is unknown. Finally, we utilized induced sputum rather 
than BAL, often considered the gold standard procedure for sampling of the lower airway  microbiome35. How-
ever, due to subclinical microaspiration and bronchial mucosa migration, lung bacterial communities largely 
resemble those in the  mouth36,37 and the most abundant pathogen in sputum generally reflects the predominant 
taxa identified in  BAL38. Further, the cystic fibrosis literature supports sputum induction as a non-invasive sur-
rogate for bronchoalveolar  lavage39.
In conclusion, we determined through culture-independent 16S rRNA sequencing that an oral microbiota 
profile dominated by Haemophilus-, Moraxella-, and Neisseria, relative to one dominated by Streptococcus or 
Prevotella, was associated with chronic lung disease among older children with well-controlled HIV infection. 
We demonstrated the plausibility of this finding mechanistically with epithelial cell gene expression experi-
ments. Prospective longitudinal studies that demonstrate an in vivo microbial or metabolic change preceding 
comprehensive chronic lung disease phenotypes are now needed.
Materials and methods
Study subjects. We undertook a cross-sectional study of HIV-infected children aged 6–16 years receiving 
routine outpatient HIV care at the Harare Central Hospital in Harare, Zimbabwe, between September 2014 
and June 2015. For logistical ease, the first five eligible children in the outpatient HIV clinic were consecutively 
enrolled every weekday. Recruitment was limited to those established on ART for ≥ 6 months. Children with 
signs and symptoms of acute respiratory tract infection, defined as new or worsening respiratory symptoms, 
fever, night sweats, or other systemic symptoms in the past 1 week, were excluded. Written informed consent 
from guardians and verbal consent from children was obtained prior to enrollment (University of California, 
San Francisco Human Research Protection Program #14-13648).
Data collection. Clinical investigations. Methods pertaining to data collection have been previously 
 published2. Respiratory symptoms were assessed by nurse-administered questionnaire. Spirometry was per-
formed according to American Thoracic Society (ATS) standards using EasyOne World spirometers (ndd Medi-
cal Technologies, Inc., Andover, Massachusetts, USA)40. Only spirometry data that met ATS quality criteria was 
used for analysis. All subjects underwent chest radiography and those with any radiographic abnormality on 
plain film underwent chest high-resolution computed tomography (HRCT). The radiographic findings from 
this cohort have been previously  published41. HIV-CLD was operationally defined as (1) reduced FEV1:FVC 
ratio on spirometry; (2) chronic cough (regardless of character) and/or dyspnea, defined as presence on most 
days for ≥ 4 weeks; or (3) abnormal HRCT (bronchial wall thickening, mosaic attenuation, and bronchiectasis)41.
Laboratory investigations. Blood samples were collected to establish CD4 counts (PIMA platform; Alere, 
Waltham, MA), and HIV viral load (COBAS Ampliprep/Taqman 48; Roche, Pleasanton, CA). Induced spu-
tum samples were collected using nebulized hypertonic saline. Samples were examined by Ziehl-Neelson stain 
microscopy and a single mycobacterial culture was performed on Lowenstein-Jensen media.
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16s rRNA gene profiling. Genomic DNA was extracted from 500ul of raw sputum consisting of sputum plugs 
and liquid via mechanical lysis using a modified cetyltrimethylammonium bromide (CTAB) buffer method as 
we have previously  described42. DTT was not used during the processing of sputum because of possibility that 
the 30-min incubation at 37 °C necessary for this protocol may alter sputum microbiota profiles. The V4 region 
of the 16S rRNA gene was amplified in triplicate PCR reactions as previously  described42. Purified amplicons 
were pooled and sequenced on a 151 bp × 151 bp paired end sequencing run on the Illumina Nextseq500 plat-
form (San Diego, California) containing 40% phiX. Negative controls for extraction (extraction buffers), 16S 
rRNA amplification (no template control) and sequencing (concentrated amplicon from negative controls) were 
built into the  protocol43.
Data analysis. Sequence data was converted to fastq format using bcl2fastq v2.16.0.10 and paired sequencing 
reads with a 25 bp minimum overlap were merged using FLASH v1.2.11. Merged reads were demultiplexed in 
the absence of quality filtering using QIIME (Quantitative Insights into Microbial Ecology, v1.9.1) followed by 
quality filtering using the USEARCH fastq filter (v7.0.1001) to remove reads having > 2 expected errors. Quality 
filtered reads were dereplicated at 100% identity, clustered at 97% sequence identity into operational taxonomic 
units (OTUs), had chimeras removed, and were mapped back to the resulting OTUs using USEARCH v8.0.1623. 
Taxonomy was assigned using the Greengenes database (May 2013). OTUs were filtered by (1) removing any 
OTU with the taxonomic classification of a known common contaminant present in more than half of the 
Negative Extraction Controls, (2) subtracting the maximum read counts found in any single remaining OTU 
present in Negative Extraction Controls from all samples, and (3) removing any remaining OTU that had a total 
read count across all samples less than 1/1000th of a percent of the total read counts across all samples. Finally, 
sequencing reads were rarefied to 73,265 reads/sample as described  previously42. Dominant taxon was defined 
as the taxon that exhibited the highest relative abundance within a given sample.
Respiratory epithelial gene expression assay. Sputum samples for epithelial assays were randomly selected from 
HMN or SP groups. Individual frozen sputum samples were heated to 37 °C for 10 min. Samples were vortexed 
for 60 s to fully resuspend the contents prior to microcentrifugation at 14,000 rpm for 10 min at room tem-
perature. Samples were filter sterilized by first filtering the supernatant through Whatman 0.45 μm PVDF Mini-
UniPrep filter (Cat. No. US203NPEAQU, GE Healthcare Life Sciences) followed by filtration through a 0.22 μm 
filter (Cat. No. US203NPUAQU) to obtain sterile sputum fluid (SSF).
As in prior  investigations44, human airway epithelial A549 cells were seeded at a confluent density in 96-well 
plates in fresh RPMI 1640 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% heat-inactivated 
Fetal Calf Serum (Cat. No. 9871-5244, USA Scientific), 100 U ml−1 penicillin–streptomycin (Cat. No. 10378016, 
Life Technologies, Carlsbad, CA) and incubated at 37 °C under conditions of 5%  CO2 for 24 h. Spent culture 
media was exchanged for fresh media containing SSF (1 in 4 dilution SSF in RPMI media). Triplicate exposures 
for each sputum fluid sample was performed and cells were re-incubated for 24 h. Total RNA was isolated with 
RNAqueous-Micro Kit (Cat. No. AM1931, Thermo Fisher Scientific) and digested with DNase I. First-strand 
cDNA was synthesized using 200 ng RNA with High-Capacity RNA-to-cDNA Kit (Cat. No. 4387406, Thermo 
Fisher Scientific) according to the manufacturer’s instructions.
Real-time quantitative-PCR (qPCR) was performed in triplicate using SYBR Green master mix (Cat. No. 
4368577, Life Technologies) in the QuantStudio 6 Flex Real-Time PCR System (Life Technologies, Carlsbad, 
CA)44. The PCR reaction conditions were as follows: 50 °C for 2 min, 95 °C for 10 min (1 cycle); 95 °C for 15 s 
and 60 °C for 1 min (40 cycles); and a final melting curve cycle of 95 °C for 15 s, 60 °C for 1 min and 95 °C for 
15 s. Target gene expression was normalized to β-actin expression followed by ∆CT subtraction of media-treated 
control to calculate the  2−∆∆CT (where CT is threshold cycle) value. Forward and reverse primers used for qPCR 
analysis of target genes are listed in Supplemental Table 1.
Data analysis. Our primary outcome was to determine the association of sputum bacterial community 
composition (i.e., microbiota) with HIV-CLD. We identified clusters of subjects based on bacterial community 
composition using Dirichlet Multinomial Mixture (DMM) models, an unsupervised Bayesian approach as previ-
ously  implemented42. The best fitting DMM model was determined using the Laplace approximation. Weighted 
UniFrac distance matrixes were calculated using QIIME to assess compositional dissimilarity between samples 
and visualized using PCoA plots. Permutational multivariate analysis of variance (PERMANOVA) was per-
formed using the adonis2 function in the vegan R package (version 2.5-3) to assess factors significantly explain-
ing variation in microbiota β–diversity. Differences in covariates between each DMM and all other DMMs, and 
for DMM groups 1/2 vs. DMM groups 3/4 were determined using logistic regression. P-values were adjusted for 
multiple comparisons using Benjamini–Hochberg false discovery rate correction. CD4+ results were treated as 
parametric data; other continuous variables were nonparametric, where central tendency was reported by the 
median and interquartile range (IQR) and the Mann–Whitney U test was used for equivalence testing between 
groups. Frequencies of categorical data were compared by chi-squared test, and results were considered statisti-
cally significant at p ≤ 0.05 (R Core Team, version 3.5.1/3, https ://www.R-proje ct.org/).
Methods statement. All methods in this manuscript were carried out in accordance with relevant guide-
lines and regulations. Ethical approval was obtained from the University of California, San Francisco Human 
Research Protection Program (#14-13648).
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